Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × mCRPC × talazoparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12 Prostatic Neoplasms 5 Ovarian Neoplasms 4 Advanced Solid Tumors 4 Neoplasms 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Recurrence 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hereditary Sensory and Autonomic Neuropathies 1 Fanconi Anemia, Complementation Group D1 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1

Interventions

enzalutamide 2 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡